May. 18 at 2:57 PM
$PACS post-call equity research reports I have access to. All bullish. Will probably get JPM tomorrow.
- UBS increased price target from
$44 to
$50
- RBC reiterated their
$52 price target (and PACS remains a top pick in 2026)
- Oppenheimer increased price target from
$42 to
$48. “Really impressive quarter”
With concerns around growth, occupancy, and skilled mix trends largely answered, and permanent CFO now in place, it seems the primary overhang remains the government investigation. I remain highly confused why for a stock that traded as high as
$41/42 before the Q4 print that spooked some investors, that we have now retraced back to
$37 with the company in a significantly better operating position, nicely boosting guidance, uncertainty removed, and approving a share repurchase program.
Any reasonable resolution to the government investigation shoots this up to
$50 immediately.
